Top 15 most frequently used treatment regimens overall and by LOT, including follow-up therapy
| Treatment* . | LOT1 (n = 889) . | LOT2 (n = 261) . | LOT≥3 (n = 344) . | Total (N = 1494) . |
|---|---|---|---|---|
| BR | 188 (21.1) | 151 (57.9) | 180 (52.3) | 500 (33.5) |
| FCR | 230 (25.9) | 59 (22.6) | 39 (11.3) | 320 (21.4) |
| R monotherapy | 103 (11.6) | 105 (40.2) | 116 (33.7) | 276 (18.5) |
| Ibrutinib | † | 72 (27.6) | 183 (53.2) | 249 (16.7) |
| Bendamustine | 31 (3.5) | 18 (6.9) | 67 (19.5) | 114 (7.6) |
| FR | 56 (6.3) | 23 (8.8) | 27 (7.8) | 104 (7.0) |
| Ofatumumab | † | 13 (5.0) | 79 (23.0) | 91 (6.1) |
| Chlorambucil | 41 (4.6) | 14 (5.4) | 31 (9.0) | 81 (5.4) |
| Alemtuzumab | † | 9 (3.4) | 49 (14.2) | 62 (4.1) |
| Investigational product | 14 (1.6) | 8 (3.1) | 37 (10.8) | 55 (3.7) |
| R-CVP | 23 (2.6) | 18 (6.9) | † | 50 (3.3) |
| R-CP | 24 (2.7) | 12 (4.6) | 12 (3.5) | 48 (3.2) |
| Fludarabine | 12 (1.3) | 14 (5.4) | † | 33 (2.2) |
| Lenalidomide | † | † | 23 (6.7) | 32 (2.1) |
| R plus investigational product | 17 (1.9) | † | † | 27 (1.8) |
| Treatment* . | LOT1 (n = 889) . | LOT2 (n = 261) . | LOT≥3 (n = 344) . | Total (N = 1494) . |
|---|---|---|---|---|
| BR | 188 (21.1) | 151 (57.9) | 180 (52.3) | 500 (33.5) |
| FCR | 230 (25.9) | 59 (22.6) | 39 (11.3) | 320 (21.4) |
| R monotherapy | 103 (11.6) | 105 (40.2) | 116 (33.7) | 276 (18.5) |
| Ibrutinib | † | 72 (27.6) | 183 (53.2) | 249 (16.7) |
| Bendamustine | 31 (3.5) | 18 (6.9) | 67 (19.5) | 114 (7.6) |
| FR | 56 (6.3) | 23 (8.8) | 27 (7.8) | 104 (7.0) |
| Ofatumumab | † | 13 (5.0) | 79 (23.0) | 91 (6.1) |
| Chlorambucil | 41 (4.6) | 14 (5.4) | 31 (9.0) | 81 (5.4) |
| Alemtuzumab | † | 9 (3.4) | 49 (14.2) | 62 (4.1) |
| Investigational product | 14 (1.6) | 8 (3.1) | 37 (10.8) | 55 (3.7) |
| R-CVP | 23 (2.6) | 18 (6.9) | † | 50 (3.3) |
| R-CP | 24 (2.7) | 12 (4.6) | 12 (3.5) | 48 (3.2) |
| Fludarabine | 12 (1.3) | 14 (5.4) | † | 33 (2.2) |
| Lenalidomide | † | † | 23 (6.7) | 32 (2.1) |
| R plus investigational product | 17 (1.9) | † | † | 27 (1.8) |
Data are n (%). Patients could receive any treatment regimen during multiple LOTs.
FR, fludarabine and rituximab; R-CP, rituximab, cyclophosphamide, and pentostatin; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone.
Patients could receive >1 therapy.
Not in top 15 most frequently used regimens.